Literature DB >> 24548244

Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level.

Olga Rass1, Bethea A Kleykamp1, Ryan G Vandrey1, George E Bigelow1, Jeannie-Marie Leoutsakos1, Maxine L Stitzer1, Eric C Strain1, Marc L Copersino2, Miriam Z Mintzer1.   

Abstract

Given the long-term nature of methadone maintenance treatment, it is important to assess the extent of cognitive side effects. This study investigated cognitive and psychomotor performance in 51 methadone maintenance patients (MMP) as a function of time since last methadone dose and maintenance dose level. MMP maintained on doses ranging from 40 to 200 mg (mean = 97 mg) completed a battery of psychomotor and cognitive measures across 2 sessions, during peak and trough states, in a double-blind crossover design. Peak sessions were associated with worse performance on measures of sensory processing, psychomotor speed, divided attention, and working memory, compared with trough sessions. The effects of maintenance dose were mixed, with higher dose resulting in worse performance on aspects of attention and working memory, improved performance on executive function, and no effects on several measures. Longer treatment duration was associated with better performance on some measures, but was also associated with increased sensitivity to time since last dose (i.e., worse performance at peak vs. trough) on some measures. The results suggest that cognitive functioning can fluctuate as a function of time since last dose even in MMP who have been maintained on stable doses for an extended time (mean duration in treatment = 4 years), but worsened performance at peak is limited to a subset of functions and may not be clinically significant at these modest levels of behavioral effect. For patients on stable methadone maintenance doses, maintenance at higher doses may not significantly increase the risk of performance impairment. PsycINFO Database Record (c) 2014 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24548244      PMCID: PMC4041803          DOI: 10.1037/a0035712

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  43 in total

1.  Opioid abuse and cognitive performance.

Authors:  Miriam Z Mintzer; Marc L Copersino; Maxine L Stitzer
Journal:  Drug Alcohol Depend       Date:  2004-12-10       Impact factor: 4.492

2.  Response inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation.

Authors:  B K Bracken; G H Trksak; D M Penetar; W L Tartarini; M A Maywalt; C M Dorsey; S E Lukas
Journal:  Drug Alcohol Depend       Date:  2012-04-30       Impact factor: 4.492

3.  Verbal Working Memory Load Affects Regional Brain Activation as Measured by PET.

Authors:  J Jonides; E H Schumacher; E E Smith; E J Lauber; E Awh; S Minoshima; R A Koeppe
Journal:  J Cogn Neurosci       Date:  1997-07       Impact factor: 3.225

4.  Cognitive impairment among methadone maintenance patients.

Authors:  S Darke; J Sims; S McDonald; W Wickes
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

5.  Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.

Authors:  C B Eap; M Bourquin; J Martin; J Spagnoli; S Livoti; K Powell; P Baumann; J Déglon
Journal:  Drug Alcohol Depend       Date:  2000-12-22       Impact factor: 4.492

6.  Cognitive functioning under moderate and low dosage methadone maintenance.

Authors:  W K Lombardo; B Lombardo; A Goldstein
Journal:  Int J Addict       Date:  1976

7.  Differential effects of diazepam and pentobarbital on mood and behavior.

Authors:  R R Griffiths; G E Bigelow; I Liebson
Journal:  Arch Gen Psychiatry       Date:  1983-08

8.  Alcohol placebos: you can only fool some of the people all of the time.

Authors:  R Hammersley; F Finnigan; K Millar
Journal:  Br J Addict       Date:  1992-10

9.  Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.

Authors:  Michael Soyka; Martin Lieb; Sabine Kagerer; Christina Zingg; Gabriele Koller; Peter Lehnert; Claudia Limmer; Heinrich Kuefner; Kristina Hennig-Fast
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

10.  Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.

Authors:  Pekka Rapeli; Carola Fabritius; Hannu Alho; Mikko Salaspuro; Kristian Wahlbeck; Hely Kalska
Journal:  BMC Clin Pharmacol       Date:  2007-06-12
View more
  6 in total

1.  Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.

Authors:  Kathleen M Carroll; Charla Nich; Elise E DeVito; Julia M Shi; Mehmet Sofuoglu
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

Review 2.  The Cholinergic System as a Treatment Target for Opioid Use Disorder.

Authors:  Kevin P Jensen; Elise E DeVito; Sarah Yip; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 3.  Neuroscience-informed psychoeducation for addiction medicine: A neurocognitive perspective.

Authors:  Hamed Ekhtiari; Tara Rezapour; Robin L Aupperle; Martin P Paulus
Journal:  Prog Brain Res       Date:  2017-10-06       Impact factor: 2.453

4.  Suppressor capacity of copper nanoparticles biosynthesized using Crocus sativus L. leaf aqueous extract on methadone-induced cell death in adrenal phaeochromocytoma (PC12) cell line.

Authors:  Peng Zhang; Jian Cui; Shirin Mansooridara; Atoosa Shahriyari Kalantari; Akram Zangeneh; Mohammad Mahdi Zangeneh; Nastaran Sadeghian; Parham Taslimi; Ramazan Bayat; Fatih Şen
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

5.  Integrating Cognitive Dysfunction Accommodation Strategies into an HIV Prevention Session: A 2-Arm Pilot Feasibility Study.

Authors:  Colleen Mistler; Michael Copenhaver
Journal:  Int J Environ Res Public Health       Date:  2022-08-01       Impact factor: 4.614

6.  Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment.

Authors:  Victoria Sanborn; John Gunstad; Roman Shrestha; Colleen B Mistler; Michael M Copenhaver
Journal:  Appl Neuropsychol Adult       Date:  2020-05-28       Impact factor: 2.050

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.